Artelo Biosciences Stock Quote ARTL - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.28

Bid

1.25

Ask

1.55

Volume

0.00 Day's Range 0.00

1.15 52 Week Range 2.98

Market Cap

4.082M

Previous Close

1.28

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

15,457

Shares Outstanding

3,188,959

Dividend Yield

PE Ratio

-0.44

Earnings Per Share (EPS)

-2.91

Revenue

Net Profit

-9.29M

Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approa... Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.artelobio.com

Headquarters

Fernley, Nevada, USA

Founded

1970

Artelo Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARTL. The last closing price for Artelo Biosciences was $1.28. Over the last year, Artelo Biosciences shares have traded in a share price range of $ 1.15 to $ 2.98.

Artelo Biosciences currently has 3,188,959 shares outstanding. The market capitalization of Artelo Biosciences is $4.08 million. Artelo Biosciences has a price to earnings ratio (PE ratio) of -0.44.

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to...

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to...

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

SOLANA BEACH, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

SOLANA BEACH, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

$12.9 Million in Cash and Investments as of September 30, 2023;Runway Expected to Reach Meaningful Development Milestones On Track to Submit IND Application with the FDA for ART26.12 During the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.27	-17.4193548387	1.55	1.5699	1.25	15520	1.3469471	CS
4	-0.19	-12.925170068	1.47	1.5999	1.25	10071	1.43753467	CS
12	-0.08	-5.88235294118	1.36	1.75	1.25	15457	1.50321712	CS
26	-0.18	-12.3287671233	1.46	1.75	1.15	17372	1.42474775	CS
52	-1.39	-52.0599250936	2.67	2.98	1.15	80321	1.82825542	CS
156	0.07	5.78512396694	1.21	7.2	0.2599	970800	1.03736497	CS
260	-3.67	-74.1414141414	4.95	7.2	0.2599	1265624	1.41923795	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ZCMDZhongchao Inc	$ 3.00 (106.90%)	13.64M
RWODRedwoods Acquisition Corporation	$ 13.37 (67.20%)	2.15M
RWODURedwoods Acquisition Corporation	$ 17.50 (65.41%)	3.11k
EGOXNext e GO NV	$ 0.0461 (28.06%)	29.73M
WLGSWang and Lee Group Inc	$ 0.6266 (25.32%)	745.46k
DCFCTritium DCFC Ltd	$ 1.41 (-61.26%)	346.93k
NXLNexalin Technologies Inc	$ 1.07 (-27.21%)	92.76k
AEISAdvanced Energy Industries Inc	$ 67.07 (-26.14%)	5
BGLCBioNexus Gene Lab Corporation	$ 0.64 (-24.58%)	63.4k
SBFMSunshine Biopharma Inc	$ 2.54 (-23.49%)	2.6M
EGOXNext e GO NV	$ 0.0461 (28.06%)	29.73M
ZCMDZhongchao Inc	$ 3.00 (106.90%)	13.64M
SINTSiNtx Technologies Inc	$ 0.04095 (2.38%)	10.18M
SQQQProShares UltraPro Short QQQ	$ 12.10 (0.25%)	6.87M
TQQQProShares UltraPro QQQ	$ 52.72 (-0.06%)	4.11M